Is Preoperative Eosinopenia an Independent Predictor of Early Mortality for Coronary Artery Bypass Surgery?
AbstractObjective: Coronary artery bypass graft surgery in one of the most effective and widely used methods employed in the treatment of ischemic heart disease, but many factors to various degrees are directly associated with perioperative and postoperative problems. In this study, we evaluated the relationship between preoperative eosinophil count and postoperative mortality in patients who underwent coronary artery bypass graft operation.
Methods: A total of 241 patients (157 males, 84 females) who underwent isolated on-pump coronary artery bypass graft operation between 2011 and 2013 in two centers were evaluated retrospectively. The mean age of patients was 64 ± 11 years. After the mean 6.2 ± 0.8 month follow-up period,
36 (15%) of the 241 patients experienced cardiovascular death. Patients were classified into two groups as those who survived versus those who died.
Results: Eosinophil levels were lower among the patients who died compared to the patients who survived (0.8 [0-3.8] versus 1.7 [0-9.4] ×1000 cells/mm3; P < .001). Optimal cut-off level of eosinophils for predicting mortality was determined as ≤1.6 ×1000 cells/mm3, with a sensitivity of 85.7% and specificity of 51.0% (area under curve, 0.703; 95% CI, 0.641-0.760).
Conclusion: Eosinopenia was used as the predictor of mortality in pediatric and adult patients in the intensive care units. Eosinopenia after coronary artery bypass graft can be related to the endogenous stress hormones, and insufficiency of the existing cardiac status. Eosinophil levels can assist and facilitate risk stratification for patients with coronary artery bypass graft.
Bass DA, Gonwa TA, Szejda P, et al. 1980. Eosinopenia of acute infection: production of eosinopenia by chemotactic factors of acute inflammation. J Clin Invest 65:1265-71.
Estafanous FG, Higgins T, Loop F. 1992. A severity score for preoperative risk factors as related to morbidity and mortality in patients with coronary artery disease undergoing myocardial revascularization surgery. Curr Opin Cardiol 7:950-8.
European Study Group. 1982. Long-term results of prospective randomized study of coronary bypass surgery in stable angina pectoris. Lancet 2:1173-80.
Finks JF, Osborne NH, Birkmeyer JD. 2011. Trends in hospital volume and operative mortality for high–risk surgery. N Engl J Med 364:2128-37.
Garlanda C, Bottazzi B, Bastone A, Mantovani A. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Ann Rev Immunol 23:337-66.
Gibson PH, Croal BL, Cuthbertson BH, et al. 2007. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J 154:995-1002.
Gibson PH, Cuthbertson BH, Croal BL, et al. 2010. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 105:186-91.
Guasti L, Dentali F, Castiglioni L, et al. 2011. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. Thromb Haemost 106:591-9.
Hannan EL, Wu C, Bennett EV, et al. 2006. Risk stratification of in-hospital mortality for coronary artery bypass graft surgery. JACC 47:661-8.
Hannan EL, Qian F, Pine M, Fry DE, Whitman K, Dennison BA. 2015. The value of adding laboratory data to coronary artery bypass grafting registry data to improve models for risk-adjusting provider mortality rates. Ann Thorac Surg 99:495-501.
Heijmans JH, Maessen JG, Roekaerts PM. 2003. Risk stratification for adverse outcome in cardiac surgery. Eur J Anaesthesiol 20:515-27.
Ivanov J, Weisel RD, David TE, Naylor CD. 1998. Fifteen-year trends in risk severity and operative mortality in elderly patients undergoing coronary artery bypass graft surgery. Circulation 97:673-80.
Kim YH, Park BH, Kim MJ, et al. 2013. Prognostic usefulness of eosinopenia in the pediatric intensive care unit. J Korean Med Sci 28:114-9.
Lang RM, Bierig M, Devereux RB, et al. 2006. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 7:79-108.
Levinson AT, Casserly BP, Levy MM. 2011. Reducing mortality in severe sepsis and septic shock. Semin Respir Crit Care Med 32:195-200.
Libby P, Ridker PM, Hasson GK. 2009. Inflamasyon in atherosclerosis from pathophysiology to practice. Am Coll Cardiol 54:2129-38.
Muehlschlegel JD, Perry TE, Liu KY. 2009. Troponin is superior to electrocardiogram and creatinine kinase MB for predicting clinically significant myocardial injury after coronary artery bypass grafting. Eur Heart J 30:1574-83.
Nilsson J, Algotsson l, HÃ¶glund P, LÃ¼hrs C, Brandt J. 2006. Comparison of 19 pre-operative risk stratification models in open-heart surgery Eur Heart J 27:867-74.
Preeshagul I, Gharbaran R, Jeong KH, et al. 2013. Potential biomarkers for predicting outcomes in CABG cardiothoracic surgeries. J Cardiothorac Surg 8:176-88.
Ridker PM, Hennekens CH, Buring JE, Rifai N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-43.
Schachner T, Wiedemann D, Fetz H, Laufer G, Kocher A, Bonaros N. 2010. Influence of preoperative serum N-terminal pro-brain natriuertic peptide on the postoperative outcome and survival rates of coronary artery bypass patients. Clinics 65:1239-45.
Wang TK, Stewart RAH, Ramanathan T, Kang N, Gamble G, White HD. 2013. Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the Universal Definition of MI. Eur Heart J 2:323-33.
Wardlaw AJ. 1994. Eosinophils in the 1990s: New perspectives on their role in health and disease. Postgrad Med J 70:536-52.
Wouters SC, Noyez L, Verheugt FW, Brouwer RM. 2002. Preoperative prediction of early mortality and morbidity in coronary bypass surgery. Cardiovasc Surg 10:500-5.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).